Search from website
Search from website
Icosagen participates in several international and national research programmes and projects. Enterprise Estonia (EAS) was, until 2022, the largest institution in Estonia responsible for implementing European Union structural funds for the national support system aimed at entrepreneurs, research institutions, and the public and non-profit sectors. At the beginning of 2022, EAS merged with KredEx, and the legal name of the new organization is the Estonian Business and Innovation Agency.
The objective of the project is to assess the cybersecurity level of Icosagen Cell Factory OÜ. Project funding: the project is funded by the European Cyber Competence Centre and its members.
Project funding: up to 4 800 €
Project duration: 21.02.2024–20.06.2024
The objective of the project is to digitalise the company’s core processes and create the necessary conditions for the successful launch of the GMP (Good Manufacturing Practice) facility.
Project funding: Up to 299,212.63 € from the European Union Recovery and Resilience Facility (NextGenerationEU)
Project duration: 01.09.2023 – 30.04.2025
The objective of the project is to develop the active component (antigen) of an intranasally administered and room-temperature stable COVID-19 vaccine candidate, along with its production technology.
Project funding: up to 300,328.50 €
Project duration: 01.09.2021 – 31.08.2023
2014–2020.4.02.21-0314 Development of therapeutic IgA molecules and expression platform for SARS-CoV (sIgA-Covid).
The objective of the project is to develop an innovative development platform for therapeutic antibodies against respiratory viruses, based on secretory immunoglobulin A (sIgA) antibodies.
Project funding: up to 2 968 871,71 €
Project duration: 01.02.2021 – 31.12.2023
Development of a technological platform for creating preparations that neutralise SARS-CoV-2 and other respiratory viruses from the colostrum of hyperimmunised cows (BioMask).
The objective of the project is to develop technologies for producing solutions against respiratory tract viruses using colostrum from cows immunised with viral proteins.
Project funding: up to 2 105 595,15 €
Project duration: 01.01.2021 – 31.07.2023
The objective of the project is to strengthen Icosagen Cell Factory’s CRO activities through the acquisition of infrastructure. Specifically, the procured equipment will significantly enhance the throughput of antibody development and offer novel capabilities for providing analytical characterization services for proteins and antibodies.
Project funding: up to 1,976,857.43 € from the support measure for infrastructure of enterprises providing research and development services
Project duration: 30.11.2023 – 01.03.2025
The objective of the project is to develop a biological drug candidate for the treatment of malignant tumors, targeting the CLDN6 and CD3 proteins.
Project funding: up to 1 994 078,52 € from the support measure for applied research and subsequent product development
Project duration: 01.01.2024 – 31.12.2026
The objective of the project is to develop next-generation phage display technology—special antibody-based libraries—to better identify specific unstructured linear regions of proteins.
Project funding: up to 1 994 078,52 € from the support measure for applied research and subsequent product development
Project duration: 01.01.2024 – 31.08.2026
The objectives of the project are:
1. To develop CD19 CAR T-cell therapy and conduct preclinical studie
2. To establish local cell therapy development, manufacturing, and treatment capabilities in Estonia
3. To develop cell therapy and chimeric antigen receptor (CAR) services at ICF, based on the discovery of new anti-cancer antibodies, their applications as CARs in cell therapy, and innovative production technologies.
Project funding: up to 1 032 777,39 € from the support measures for applied research and subsequent product development
Project duration: 01.05.2024 – 30.04.2026
Enterprise Estonia is the largest institution implementing EU structural funds in Estonia for the national support system for entrepreneurship, research institutions, public and non-profit sectors.
INTENSO — Gaining Productivity, Cost Efficiency and Sustainability in the Downstream Processing of Bio Products by Novel Integration and Intensification StrategiesThe Intenso project is about identifying the bottlenecks in the currently used downstream processing methods, and finding new solutions to circumvent them. This is highly relevant for any and all biotechnical products, as downstream processes account for more than 80% of the manufacturing costs. The Intenso approach will not concentrate solely on the effectiveness of the new methods, but will strive to lead to a sustainable approach, factoring in risk management derived from economic, environmental, and social developments, also including government policies and legal constraints.
Project period: August 1, 2012 — January 31, 2017.
More information about Intenso: http://intensoproject.eu/
MAARS — Microbes in Allergy and Autoimmunity Related to the SkinMAARS is an international and multicentre study that explores the nature and duration of microbial stimuli and associated changes in the epithelial barrier leading to the development of skin-related allergy and autoimmunity. The aim of the study is to identify microbe-host-interaction networks involved in the development and persistence of atopic dermatitis and psoriasis. The project will pave the way for progress in prevention, new diagnostic strategies and treatment options for allergy and autoimmune related skin diseases.
Project period: April 1, 2011 — March 31, 2015.
More information about MAARS: http://www.maars.eu/
EURIPRED — European Research Infrastructures for Poverty Related DiseasesEURIPRED is a collaborative infrastructure programme with the objective to reinforce the knowledge infrastructure across poverty related diseases. The overall goal of EURIPRED is to coordinate and integrate international resources into a single specialized infrastructure to support European HIV, Tuberculosis, Malaria and Hepatitis B and Hepatitis C studies from early drug, vaccine and microbicide discovery to clinical trials.
Project period: November 1, 2013 — October 31, 2017.
More information about EURIPRED: http://www.euripred.eu/home.htm
IcoCell — Chassis for Enhanced Mammalian Cell Line Development and Engineering
The opportunity to focus on the production of biopharmaceuticals is often taken from SMEs since huge amount of resources is required for the development of high-producer cell lines. We envision that our parental cell factories will increase the efficiency of cell line engineering and will effectively reduce the time-to-market for mammalian cell-based products. It allows SMEs to leverage their traditional strengths of adaptability and creativity, and to develop novel products for biotechnology industries.
Project period: April 1, 2015 — September 30, 2015.
The Archimedes Foundation was established by the Estonian government to coordinate and implement different international and national programmes and projects in the field of training, education and research. Archimedes Foundation granted projects are performed in collaboration with the University of Tartu.
© 2026 Icosagen
